Skip to main content
Press Release

ObvioHealth Welcomes Scott Dixon as Chief Commercial Officer

Download the PDF

‍Executive with more than 25 years of health and technology experience joins growing VRO.

‍

‍NEW YORK, August 31, 2022 - ObvioHealth, a leading global virtual research organization (VRO) delivering end-to-end decentralized clinical trials, today announces Scott Dixon as the company’s new Chief Commercial Officer. Dixon’s results-driven mindset is leading ObvioHealth’s commercial team in the successful global rollout of its next-generation DCT platform and app.  

‍

“ObvioHealth is empowering clinical trial sponsors to capture stronger evidence through its innovative use of technology,” said Dixon. “I’m truly excited to lead our commercial and strategic partnerships, as well as our experienced service and delivery teams, to help our clients adopt ObvioHealth’s cutting-edge, digital DCT solutions.”  

‍

During his 25+ year career, Dixon has integrated commercial and operational planning for life science, pharmaceutical, and healthcare software companies, including ERT, Oracle, Phase Forward, WebMD and Parexel. Most recently, he served as Chief Revenue Officer at Flywheel.io. His experience overseeing clinical development processes, as well as direct-to-patient technology, has resulted in successful breakthrough offerings for startups and Fortune 100 companies.  

‍

“We are ecstatic to bring Scott on board, and believe his multi-faceted experience across operations, product, and sales divisions will bring valuable expertise to ObvioHealth,” said Ivan Jarry, CEO of ObvioHealth. “We look forward to his contributions to our ambitious and strategic roadmap moving forward.”

‍

Press Release

ObvioHealth Welcomes Scott Dixon as Chief Commercial Officer

No items found.
Download the PDF

‍Executive with more than 25 years of health and technology experience joins growing VRO.

‍

‍NEW YORK, August 31, 2022 - ObvioHealth, a leading global virtual research organization (VRO) delivering end-to-end decentralized clinical trials, today announces Scott Dixon as the company’s new Chief Commercial Officer. Dixon’s results-driven mindset is leading ObvioHealth’s commercial team in the successful global rollout of its next-generation DCT platform and app.  

‍

“ObvioHealth is empowering clinical trial sponsors to capture stronger evidence through its innovative use of technology,” said Dixon. “I’m truly excited to lead our commercial and strategic partnerships, as well as our experienced service and delivery teams, to help our clients adopt ObvioHealth’s cutting-edge, digital DCT solutions.”  

‍

During his 25+ year career, Dixon has integrated commercial and operational planning for life science, pharmaceutical, and healthcare software companies, including ERT, Oracle, Phase Forward, WebMD and Parexel. Most recently, he served as Chief Revenue Officer at Flywheel.io. His experience overseeing clinical development processes, as well as direct-to-patient technology, has resulted in successful breakthrough offerings for startups and Fortune 100 companies.  

‍

“We are ecstatic to bring Scott on board, and believe his multi-faceted experience across operations, product, and sales divisions will bring valuable expertise to ObvioHealth,” said Ivan Jarry, CEO of ObvioHealth. “We look forward to his contributions to our ambitious and strategic roadmap moving forward.”

‍

Press Release

ObvioHealth Welcomes Scott Dixon as Chief Commercial Officer

No items found.
Download the PDF

‍Executive with more than 25 years of health and technology experience joins growing VRO.

‍

‍NEW YORK, August 31, 2022 - ObvioHealth, a leading global virtual research organization (VRO) delivering end-to-end decentralized clinical trials, today announces Scott Dixon as the company’s new Chief Commercial Officer. Dixon’s results-driven mindset is leading ObvioHealth’s commercial team in the successful global rollout of its next-generation DCT platform and app.  

‍

“ObvioHealth is empowering clinical trial sponsors to capture stronger evidence through its innovative use of technology,” said Dixon. “I’m truly excited to lead our commercial and strategic partnerships, as well as our experienced service and delivery teams, to help our clients adopt ObvioHealth’s cutting-edge, digital DCT solutions.”  

‍

During his 25+ year career, Dixon has integrated commercial and operational planning for life science, pharmaceutical, and healthcare software companies, including ERT, Oracle, Phase Forward, WebMD and Parexel. Most recently, he served as Chief Revenue Officer at Flywheel.io. His experience overseeing clinical development processes, as well as direct-to-patient technology, has resulted in successful breakthrough offerings for startups and Fortune 100 companies.  

‍

“We are ecstatic to bring Scott on board, and believe his multi-faceted experience across operations, product, and sales divisions will bring valuable expertise to ObvioHealth,” said Ivan Jarry, CEO of ObvioHealth. “We look forward to his contributions to our ambitious and strategic roadmap moving forward.”

‍

Press Release

ObvioHealth Welcomes Scott Dixon as Chief Commercial Officer

No items found.
Download the PDF

‍Executive with more than 25 years of health and technology experience joins growing VRO.

‍

‍NEW YORK, August 31, 2022 - ObvioHealth, a leading global virtual research organization (VRO) delivering end-to-end decentralized clinical trials, today announces Scott Dixon as the company’s new Chief Commercial Officer. Dixon’s results-driven mindset is leading ObvioHealth’s commercial team in the successful global rollout of its next-generation DCT platform and app.  

‍

“ObvioHealth is empowering clinical trial sponsors to capture stronger evidence through its innovative use of technology,” said Dixon. “I’m truly excited to lead our commercial and strategic partnerships, as well as our experienced service and delivery teams, to help our clients adopt ObvioHealth’s cutting-edge, digital DCT solutions.”  

‍

During his 25+ year career, Dixon has integrated commercial and operational planning for life science, pharmaceutical, and healthcare software companies, including ERT, Oracle, Phase Forward, WebMD and Parexel. Most recently, he served as Chief Revenue Officer at Flywheel.io. His experience overseeing clinical development processes, as well as direct-to-patient technology, has resulted in successful breakthrough offerings for startups and Fortune 100 companies.  

‍

“We are ecstatic to bring Scott on board, and believe his multi-faceted experience across operations, product, and sales divisions will bring valuable expertise to ObvioHealth,” said Ivan Jarry, CEO of ObvioHealth. “We look forward to his contributions to our ambitious and strategic roadmap moving forward.”

‍

Press Release

ObvioHealth Welcomes Scott Dixon as Chief Commercial Officer

No items found.
Download the PDF

‍Executive with more than 25 years of health and technology experience joins growing VRO.

‍

‍NEW YORK, August 31, 2022 - ObvioHealth, a leading global virtual research organization (VRO) delivering end-to-end decentralized clinical trials, today announces Scott Dixon as the company’s new Chief Commercial Officer. Dixon’s results-driven mindset is leading ObvioHealth’s commercial team in the successful global rollout of its next-generation DCT platform and app.  

‍

“ObvioHealth is empowering clinical trial sponsors to capture stronger evidence through its innovative use of technology,” said Dixon. “I’m truly excited to lead our commercial and strategic partnerships, as well as our experienced service and delivery teams, to help our clients adopt ObvioHealth’s cutting-edge, digital DCT solutions.”  

‍

During his 25+ year career, Dixon has integrated commercial and operational planning for life science, pharmaceutical, and healthcare software companies, including ERT, Oracle, Phase Forward, WebMD and Parexel. Most recently, he served as Chief Revenue Officer at Flywheel.io. His experience overseeing clinical development processes, as well as direct-to-patient technology, has resulted in successful breakthrough offerings for startups and Fortune 100 companies.  

‍

“We are ecstatic to bring Scott on board, and believe his multi-faceted experience across operations, product, and sales divisions will bring valuable expertise to ObvioHealth,” said Ivan Jarry, CEO of ObvioHealth. “We look forward to his contributions to our ambitious and strategic roadmap moving forward.”

‍

Press Release

ObvioHealth Welcomes Scott Dixon as Chief Commercial Officer

No items found.
Download the PDF

‍Executive with more than 25 years of health and technology experience joins growing VRO.

‍

‍NEW YORK, August 31, 2022 - ObvioHealth, a leading global virtual research organization (VRO) delivering end-to-end decentralized clinical trials, today announces Scott Dixon as the company’s new Chief Commercial Officer. Dixon’s results-driven mindset is leading ObvioHealth’s commercial team in the successful global rollout of its next-generation DCT platform and app.  

‍

“ObvioHealth is empowering clinical trial sponsors to capture stronger evidence through its innovative use of technology,” said Dixon. “I’m truly excited to lead our commercial and strategic partnerships, as well as our experienced service and delivery teams, to help our clients adopt ObvioHealth’s cutting-edge, digital DCT solutions.”  

‍

During his 25+ year career, Dixon has integrated commercial and operational planning for life science, pharmaceutical, and healthcare software companies, including ERT, Oracle, Phase Forward, WebMD and Parexel. Most recently, he served as Chief Revenue Officer at Flywheel.io. His experience overseeing clinical development processes, as well as direct-to-patient technology, has resulted in successful breakthrough offerings for startups and Fortune 100 companies.  

‍

“We are ecstatic to bring Scott on board, and believe his multi-faceted experience across operations, product, and sales divisions will bring valuable expertise to ObvioHealth,” said Ivan Jarry, CEO of ObvioHealth. “We look forward to his contributions to our ambitious and strategic roadmap moving forward.”

‍

Press Release

ObvioHealth Welcomes Scott Dixon as Chief Commercial Officer

Download the PDF

‍Executive with more than 25 years of health and technology experience joins growing VRO.

‍

‍NEW YORK, August 31, 2022 - ObvioHealth, a leading global virtual research organization (VRO) delivering end-to-end decentralized clinical trials, today announces Scott Dixon as the company’s new Chief Commercial Officer. Dixon’s results-driven mindset is leading ObvioHealth’s commercial team in the successful global rollout of its next-generation DCT platform and app.  

‍

“ObvioHealth is empowering clinical trial sponsors to capture stronger evidence through its innovative use of technology,” said Dixon. “I’m truly excited to lead our commercial and strategic partnerships, as well as our experienced service and delivery teams, to help our clients adopt ObvioHealth’s cutting-edge, digital DCT solutions.”  

‍

During his 25+ year career, Dixon has integrated commercial and operational planning for life science, pharmaceutical, and healthcare software companies, including ERT, Oracle, Phase Forward, WebMD and Parexel. Most recently, he served as Chief Revenue Officer at Flywheel.io. His experience overseeing clinical development processes, as well as direct-to-patient technology, has resulted in successful breakthrough offerings for startups and Fortune 100 companies.  

‍

“We are ecstatic to bring Scott on board, and believe his multi-faceted experience across operations, product, and sales divisions will bring valuable expertise to ObvioHealth,” said Ivan Jarry, CEO of ObvioHealth. “We look forward to his contributions to our ambitious and strategic roadmap moving forward.”

‍

Case Study

When older DCT subjects are more compliant than their

ObvioHealth recently completed the first-ever fully virtual urogynecology study to evaluate a medical digital intravaginal device for female stress urinary incontinence. In this randomized trial, pelvic floor muscle contractions were monitored.

350

Participants in 
14 weeks

350

Participants in 
14 weeks
*$67 Per Participant
Read the Case Study
Second Link Here

Discover More Case Studies

Discover More News

Discover More White Papers

Discover More Blogs

Discover More Playbooks

Discover More Webinars

Discover More Events

No items found.

ObvioHealth and Sterling IRB Partner to Accelerate Access to Clinical Trials

ObvioHealth and Sterling IRB today announce a partnership to help speed access and adoption of decentralized clinical trials. The partnership makes Sterling IRB the preferred Institutional Review Board for ObvioHealth.

› Read More
No items found.

ObvioHealth Secures $17 Million in Latest Investment Round​

ObvioHealth, a leading virtual health research organization or VRO, announced today it has raised $17 million in its latest round of financing. This round of financing comes on the heels of a global alliance with a strategic partner announced in March.

› Read More